Product Images Isosorbide Dinitrate And Hydralazine Hydrochloride

This is a Kaplan-Meier plot showing the time to death in Black patients from the A-HeFT study. The plot compares the impact of Isosorbide Dinitrate and Hydralazine Hydrochloride versus Placebo, indicating a significant 43% reduction in mortality. The x-axis represents time in days, and the y-axis shows the number of patients at risk.*

This text presents a Kaplan-Meier plot showing a 39% risk reduction in first hospitalization for heart failure in Black patients from the A-HeFT study. It compares the time to first hospitalization for heart failure between Isosorbide Dinitrate and Hydralazine Hydrochloride tablets group (N=518) and Placebo group (N=532). The plot also indicates that the risk reduction is statistically significant with a P-value of less than 0.001 based on the Log-Rank Test. Time is represented in days on the x-axis, showing the percentage of patients without hospitalization over time.*

This is a medication containing isosorbide dinitrate and hydralazine in the form of tablets. Each tablet has 20 mg of isosorbide dinitrate and 37.5 mg of hydralazine. The tablets should be stored at room temperature between 15°C - 30°C (59°F - 86°F). The usual dosage instructions can be found on the package insert. This medication is distributed by A2A Integrated Pharmaceuticals and is prescribed under Rx Only. Each pack contains 180 tablets.*

This text provides information about a medication labeled as NDC 73141-012-03, containing 20 mg isosorbide dinitrate and 37.5 mg Hydralazine HCl per tablet. The storage recommendation is to store at room temperature. The typical dosage instructions can be found in the package insert. The medication is distributed by A2A Integrated Pharmaceuticals in Bowling Green, KY, with a total of 90 tablets in the package.*